| Literature DB >> 36062610 |
Samara M A Jansen1, Anna E Huis In 't Veld1, Peter Hans C G Tolen2, Wouter Jacobs3, H M Willemsen3, Hans P Grotjohan4, Marc Waskowsky4, Jan van der Maten5, Arno van der Weerdt5, Romke Hoekstra6, Ana J Pérez Matos6, Maria J Overbeek7, Sjoerd A Mollema7, Lahssan H Hassan El Bouazzaoui2, Joris W J Vriend2, J Milena M Roorda8, Ramon de Nooijer8, Ivo van der Lee9, A J Voogel9, Johannes C Post10, Thomas Macken11, Jacqueline M Aerts11, Marjo J T van de Ven12, Heidi Bergman12, Mirjam Bakker-de Boo13, Roline C de Boer13, Anton Vonk Noordegraaf1, Frances S de Man1, Harm Jan Bogaard1.
Abstract
Background Recognition of precapillary pulmonary hypertension (PH) has significant implications for patient management. However, the low a priori chance to find this rare condition in community hospitals may create a barrier against performing a right heart catheterization (RHC). This could result in misclassification of PH and delayed diagnosis/treatment of precapillary PH. Therefore, we investigated patient characteristics and echocardiographic parameters associated with the decision whether to perform an RHC in patients with incident PH in 12 Dutch community hospitals. Methods and Results In total, 275 patients were included from the OPTICS (Optimizing PH Diagnostic Network in Community Hospitals) registry, a prospective cohort study with patients with incident PH; 157 patients were diagnosed with RHC (34 chronic thromboembolic PH, 38 pulmonary arterial hypertension, 81 postcapillary PH, 4 miscellaneous PH), while 118 patients were labeled as probable postcapillary PH without hemodynamic confirmation. Multivariable analysis showed that older age (>60 years), left ventricular diastolic dysfunction grade 2-3, left atrial dilatation were independently associated with the decision to not perform an RHC, while presence of prior venous thromboembolic events or pulmonary arterial hypertension-associated conditions, right atrial dilatation, and tricuspid regurgitation velocity ≥3.7 m/s favor an RHC performance. Conclusions Older age and echocardiographic parameters of left heart disease were independently associated with the decision to not perform an RHC, while presence of prior venous thromboembolic events or pulmonary arterial hypertension-associated conditions, right atrial dilation, and severe PH on echocardiography favored an RHC performance. As such, especially elderly patients may be at an increased risk of diagnostic delays and missed diagnoses of treatable precapillary PH, which could lead to a worse prognosis.Entities:
Keywords: diagnosis; elderly; pulmonary hypertension
Mesh:
Year: 2022 PMID: 36062610 PMCID: PMC9496424 DOI: 10.1161/JAHA.121.025143
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 6.106
Figure 1Flowchart representing patients’ numbers and study methods.
CTEPH indicates chronic thromboembolic pulmonary hypertension; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; and RHC, right heart catheterization.
Characteristics of Patients in Whom RHC is Performed Versus No RHC
| RHC not performed | RHC performed |
| |
|---|---|---|---|
| Patients, n | 118 | 157 | |
| Sex (Women), n (%) | 83 (70%) | 82 (52%) | 0.004 |
| Age, y | 76±9 | 67±12 | <0.001 |
| BMI, kg/m2 | 28.6±5.6 | 29.7±6.8 | 0.218 |
| Comorbidities | |||
| Hypertension, n (%) | 99 (84%) | 114 (73%) | 0.038 |
| Hypercholesterolemia, n (%) | 49 (42%) | 60 (38%) | 0.667 |
| Diabetes, n (%) | 34 (29%) | 40 (25%) | 0.631 |
| Coronary artery disease, n (%) | 33 (28%) | 44 (28%) | 1.000 |
| Obesity, n (%) | 38 (32%) | 57 (36%) | 0.562 |
| AF, n (%) | 58 (49%) | 44 (28%) | 0.001 |
| COPD, n (%) | 14 (12%) | 23 (15%) | 0.623 |
| Prior VTE, n (%) | 8 (7%) | 41 (26%) | <0.001 |
| PAH‐associated conditions, n (%) | 4 (3%) | 32 (21%) | <0.001 |
| No. of comorbidities | 3 [2–4] | 3 [2–4] | 0.760 |
| Echocardiography | |||
| LV hypertrophy, n (%) | 39 (33%) | 39 (25%) | 0.715 |
| LA dilatation, n (%) | 89 (75%) | 76 (48%) | <0.001 |
| TRV ≥3.7 m/s, n (%) | 10 (8%) | 50 (32%) | <0.001 |
| TRV (m/s) | 3.2±0.3 | 3.5±0.6 | <0.001 |
| RV dilatation, n (%) | 34 (29%) | 83 (53%) | <0.001 |
| RA dilatation, n (%) | 57 (48%) | 91 (58%) | 0.032 |
| Overt diastolic dysfunction grade 2–3, n (%) | 38 (32%) | 25 (16%) | <0.001 |
| E/e’ | 11.7 [9.6–15.1] | 9.9 [6.5–12.8] | 0.002 |
| E/A | 1.1 [0.8–1.5] | 0.8 [ 0.6–1.1] | <0.001 |
| NT‐proBNP >300 ng/L, n (%) | 51 (43%) | 81 (52%) | 0.906 |
| NT‐proBNP (ng/L) | 1150 [444–2635] | 1281 [509–3049] | 0.703 |
Data are given as mean (SD), median (interquartile range) or percentages (%). AF indicates atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; E/e’, ratio of early diastolic mitral inflow velocity to early diastolic mitral annular tissue velocity; E/A, ratio of early diastolic mitral inflow velocity to late diastolic mitral peak A velocity; LA, left atrial; LVH, left ventricular hypertrophy; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; RA, right atrial; RHC, right heart catheterization; RV, right ventricular; TRV, tricuspid regurgitation velocity; and VTE, venous thromboembolic event.
Total number of comorbidities (min 0‐max 9). PAH associated causes included: (connective tissue disease, congenital heart disease, liver cirrhosis, HIV, drug abuse).
Univariable and Multivariable Analysis of Predictors for the RHC Performance
| Univariable analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|
| Odds ratio | 95%CI |
| Odds ratio | 95%CI |
| Chi‐square value | |
| Age >60 y | 0.17 | 0.07–0.43 | <0.001 | 0.19 | 0.06–0.66 | 0.008 | <0.001 |
| Overt diastolic dysfunction grade 2–3 | 0.31 | 0.16–0.58 | <0.001 | 0.43 | 0.50–0.92 | 0.029 | 0.007 |
| LA dilatation | 0.33 | 0.19–0.57 | <0.001 | 0.41 | 0.19–0.90 | 0.026 | 0.007 |
| Atrial fibrillation | 0.40 | 0.24–0.67 | <0.001 | ||||
| Sex (Women) | 0.46 | 0.28–0.76 | 0.003 | ||||
| Systemic hypertension | 0.51 | 0.28–0.93 | 0.028 | ||||
| NT‐proBNP >300 ng/L | 0.85 | 0.34–2.14 | 0.726 | ||||
| Diabetes | 0.85 | 0.49–1.44 | 0.537 | ||||
| Hypercholesterolemia | 0.87 | 0.54–1.42 | 0.579 | ||||
| LV hypertrophy | 0.88 | 0.50–1.51 | 0.613 | ||||
| Coronary artery disease | 1.00 | 0.59–1.71 | 0.991 | ||||
| No. of comorbidities | 1.04 | 0.89–1.23 | 0.577 | ||||
| Obesity | 1.25 | 0.75–2.07 | 0.392 | ||||
| COPD | 1.28 | 0.63–2.60 | 0.504 | ||||
| RA dilatation | 1.78 | 1.08–2.94 | 0.024 | 3.04 | 1.37–6.73 | 0.006 | 0.006 |
| RV dilatation | 2.98 | 1.76–5.05 | <0.001 | ||||
| Prior VTE | 4.90 | 2.20–10.92 | <0.001 | 3.57 | 1.23–10.38 | 0.019 | 0.014 |
| TRV ≥3.7 m/s | 6.52 | 3.12–13.64 | <0.001 | 3.52 | 1.41–8.82 | 0.007 | <0.001 |
| PAH‐associated conditions | 7.34 | 2.52–21.44 | <0.001 | 4.03 | 1.01–16.16 | 0.049 | 0.033 |
Variables entered in the backward stepwise model in the multivariable analysis: Age above 60 years, overt diastolic dysfunction grade 2–3, left atrial dilatation, atrial fibrillation, women, systemic hypertension, right atrial dilatation, right ventricular dilatation, tricuspid regurgitation velocity ≥3.7 m/s, prior venous thromboembolic event, pulmonary arterial hypertension‐associated conditions. COPD indicates chronic obstructive pulmonary disease; LA, left atrial; LV, left ventricle; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; OR, odds ratio; PAH, pulmonary arterial hypertension; RA, right atrial; RHC, right heart catheterization; RV, right ventricle; TRV, tricuspid regurgitation velocity; and VTE, venous thromboembolic event.
Figure 2Univariable predictors for right heart catheterization performance.
AF indicates atrial fibrillation; COPD, chronic obstructive pulmonary disease; LA, left atrial; LV, left ventricular; OR, odds ratio; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; RA, right atrial; RV, right ventricular; and TRV, tricuspid regurgitation velocity.
Figure 3Independent predictors for the performance of right heart catheterization (RHC) in patients suspected of pulmonary hypertension.
A, Shows the number of patients with or without RHC according to the distribution of age. B, Shows the different stadia of diastolic dysfunction and within this group the number of RHC performance. C, The distribution of pulmonary arterial hypertension‐associated conditions (present or absent) as an independent predictor for RHC performance. D, Shows the number of patients with or without RHC performance according to the presence or absence of RA dilatation on echocardiography. E, Shows that patients suspected of pulmonary hypertension with a tricuspid regurgitation velocity ≥3.7 m/s have more RHC performed. F, Highlights that patients with a prior venous thromboembolic event received more RHCs. G, focusses on the distribution of prior VTE in patient with of without a RHC. PAH indicates pulmonary arterial hypertension; RA, right atrial; TR, tricuspid regurgitation; and VTE, venous thromboembolic events.
Figure 4Arguments not to perform a right heart catheterization (RHC) by the health care provider.
PH indicates pulmonary hypertension.